Literature DB >> 2137840

Monovalent ligands of complement receptor 2 inhibit whereas polyvalent ligands enhance anti-Ig-induced human B cell intracytoplasmic free calcium concentration.

G C Tsokos1, J D Lambris, F D Finkelman, E D Anastassiou, C H June.   

Abstract

We have performed experiments to investigate the role of ligands for complement receptor 2 (CR2) in human B cell activation. Flow microfluorimetry was used to assess changes in free intracytoplasmic calcium concentration [Ca2+] in indo-loaded B cells, immediately after exposure to anti-mu antibody and to monovalent or polyvalent CR2 ligands. As monovalent ligands we used the C3d fragment and synthetic C3 peptides (peptides P14, residues 1201-1214, and P28, residues 1187-1214). As polyvalent ligands we used i) an intact monoclonal mouse anti-CR2 antibody (HB5) and its F(ab')2 fragment, ii) tetravalent P13 [residues 1202-1214) 4-template), and iii) P28 conjugated to BSA (molar ratio 5/1). Anti-CR2 antibody HB5, tetravalent P13, and P28 conjugated to BSA, enhanced the ability of F(ab')2 fragments of the IgG fraction of goat anti-human mu antibody to increase human B cell [Ca2+]i. In contrast, the monomeric CR2 ligands C3d and P28 inhibited the anti-mu-induced increase in human B cell [Ca2+]i. Multivalent P13, P28, and the HB5, by themselves, did not affect B cell [Ca2+]i. These experiments suggest that the valence of the CR2 ligands is crucial for the nature (synergistic vs antagonistic) of the message transmitted through the CR2.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2137840

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

Review 1.  The role of complement in the acquired immune response.

Authors:  C H Nielsen; E M Fischer; R G Leslie
Journal:  Immunology       Date:  2000-05       Impact factor: 7.397

2.  Regulation of VH gene repertoire and somatic mutation in germinal centre B cells by passively administered antibody.

Authors:  H Song; X Nie; S Basu; M Singh; J Cerny
Journal:  Immunology       Date:  1999-10       Impact factor: 7.397

3.  Depletion of complement has distinct effects on the primary and secondary antibody responses to a conjugate of pneumococcal serotype 14 capsular polysaccharide and a T-cell-dependent protein carrier.

Authors:  Samuel T Test; Joyce K Mitsuyoshi; Yong Hu
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

Review 4.  Role of complement and Fc receptors in the pathogenesis of HIV-1 infection.

Authors:  D C Montefiori
Journal:  Springer Semin Immunopathol       Date:  1997

Review 5.  Cellular signalling mechanisms in B lymphocytes.

Authors:  W Cushley; M M Harnett
Journal:  Biochem J       Date:  1993-06-01       Impact factor: 3.857

6.  Increased immunogenicity and induction of class switching by conjugation of complement C3d to pneumococcal serotype 14 capsular polysaccharide.

Authors:  S T Test; J Mitsuyoshi; C C Connolly; A H Lucas
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

7.  Induction of interleukin-6 after stimulation of human B-cell CD21 by Epstein-Barr virus glycoproteins gp350 and gp220.

Authors:  J E Tanner; C Alfieri; T A Chatila; F Diaz-Mitoma
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

8.  Complement receptor expression and activation of the complement cascade on B lymphocytes from patients with systemic lupus erythematosus (SLE).

Authors:  H V Marquart; A Svendsen; J M Rasmussen; C H Nielsen; P Junker; S E Svehag; R G Leslie
Journal:  Clin Exp Immunol       Date:  1995-07       Impact factor: 4.330

9.  Intersection of the complement and immune systems: a signal transduction complex of the B lymphocyte-containing complement receptor type 2 and CD19.

Authors:  A K Matsumoto; J Kopicky-Burd; R H Carter; D A Tuveson; T F Tedder; D T Fearon
Journal:  J Exp Med       Date:  1991-01-01       Impact factor: 14.307

10.  The structure of an alternate form of complement C3 that displays costimulatory growth factor activity for B lymphocytes.

Authors:  Y Cahen-Kramer; I L Mårtensson; F Melchers
Journal:  J Exp Med       Date:  1994-12-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.